Antineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantInflammationInflammation MediatorsCytokinesTumor Necrosis Factor-alphaInterleukin-8LipopolysaccharidesNF-kappa BInterleukin-6MacrophagesMice, Inbred C57BLAntineoplastic AgentsCells, CulturedCombined Modality TherapyCisplatinToll-Like Receptor 4Breast NeoplasmsSignal TransductionToll-Like Receptor 2Lung NeoplasmsRNA, MessengerCyclophosphamideTreatment OutcomeMice, KnockoutInterleukin-1betaSurvival AnalysisMonocytesDisease-Free SurvivalReverse Transcriptase Polymerase Chain ReactionCell LineSurvival RateDoxorubicinPrognosisNeoplasm StagingUp-RegulationOvarian NeoplasmsMyeloid Differentiation Factor 88Seoul virusGene Expression RegulationNeoplasmsEarly Detection of CancerChemokinesInterleukin-1Epithelial CellsNeoplasm MetastasisImmunity, InnateToll-Like ReceptorsDisease Models, AnimalCell Line, TumorTime FactorsStomach NeoplasmsLungDrug Resistance, NeoplasmApoptosisDose-Response Relationship, DrugBlotting, WesternEtoposideNeoadjuvant TherapyDrug Administration ScheduleEnzyme-Linked Immunosorbent AssayNeoplasm Recurrence, LocalInterleukin-10Mice, Inbred BALB CPaclitaxelGene Expression ProfilingGene ExpressionMicrogliaCarcinoma, Non-Small-Cell LungFollow-Up StudiesColonic NeoplasmsDown-RegulationChemokine CCL2NeutrophilsProstatic NeoplasmsMacrophage ActivationFlow CytometryTaxoidsMethotrexateCarboplatinColorectal NeoplasmsPancreatic NeoplasmsInterferon-gammaCyclooxygenase 2Prospective StudiesDeoxycytidineEndothelial CellsDisease ProgressionAntimetabolites, AntineoplasticAnti-Inflammatory AgentsVinblastinep38 Mitogen-Activated Protein KinasesNeoplasm InvasivenessRNA, Small InterferingGene Expression Regulation, NeoplasticNitric Oxide Synthase Type IIHMGB1 ProteinToll-Like Receptor 9Antineoplastic Agents, PhytogenicCarcinoma, Squamous Cell